HER3 Blocker and Immune Checkpoint Modulator Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for head and neck squamous cell carcinoma (HNSCC) have limited effectiveness, particularly for patients who do not respond to anti-PD-1 treatment, due to immune suppressive mechanisms and overreliance on the PI3K/mTOR signaling pathway for tumor growth, which limits the potential benefits of combining mTOR inhibitors with immune oncology agents.
Innovation Solution
Administering a HER3 blocker, such as an anti-HER3 antibody or CDX-3379, in combination with an immune checkpoint modulator to modulate the PI3K/AKT/mTOR pathway, thereby reducing tumor growth and enhancing the effectiveness of immune checkpoint blockade therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mTOR inhibitors are combined with immune oncology agents, then anti-tumor activity is enhanced, but immunosuppressive effects limit the potential benefits
Solution Approach 1:
The patent extracts and blocks the HER3 component from the PI3K/AKT/mTOR signaling pathway using anti-HER3 antibodies (e.g., CDX-3379). By specifically targeting HER3, the invention removes a key immunosuppressive element from the pathway, thereby enabling effective combination with immune oncology agents without the harmful immunosuppressive effects that limit mTOR inhibitor combinations.
2Reliability
If anti-PD-1 treatment is used, then T cell activation is enhanced, but response rate remains limited to 13% in Phase 3 trial
Solution Approach 1:
The patent merges anti-HER3 therapy with anti-PD-1 immunotherapy into a combination treatment regimen. This combination approach targets both the HER3 signaling pathway and PD-1 checkpoint simultaneously, synergistically enhancing T cell activation and overcoming the limited response rate observed with anti-PD-1 monotherapy in Phase 3 trials.
3Reliability
If HER3 blocking is combined with immune checkpoint modulation, then tumor growth is reduced and survival is prolonged, but treatment complexity increases
Solution Approach 1:
The patent uses anti-HER3 antibodies (such as CDX-3379) as intermediary agents that specifically block the HER3 receptor, thereby modulating the PI3K/AKT/mTOR pathway. This intermediary approach allows for precise control of signaling pathways while combining with immune checkpoint modulators to achieve durable responses and prolonged survival without excessive treatment complexity.
Data Source
AI summary
Disclosed herein are methods of treating HNSCC that comprises administration of a HER3 blocker and an immune checkpoint modulator. In some embodiments, also disclosed herein is a method of modulating activity level of the PI3K/AKT/mTOR pathway in a HNSCC cell to modulate proliferation or sensitization of the cancer cell to a treatment therapy.